Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CARETEQ - Executive Leadership Team Restructured For Growth (ASX:CTQ)

Careteq Limited (ASX:CTQ, "Careteq" or the "Group") is pleased to announce the restructuring of the executive leadership team to better take advantage of the many growth opportun...read more

Chimeric Therapeutics - Security Class Reinstatement to Quotation CHMO (ASX:CHM)

The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be lifted immediately. For more information, download the attached PDF.

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall (ASX:CHM)

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (Entitlement Offer). Chime...read more

Chimeric Therapeutics - CDH17 CAR T preclinical data featured in Nature Cancer (ASX:CHM)

-- A CAR T targeting the cell surface marker CDH17 (“CDH17 CAR”), currently under development by Chimeric as CHM 2101, is featured in the prestigious journal Nature Cancer, highlighting ...read more

Chimeric Therapeutics - Trading Halt (ASX:CHM)

The securities of Chimeric Therapeutics Limited (‘CHM’) will be placed in trading halt at the request of CHM, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more

Chimeric Therapeutics - Pause in Trading (ASX:CHM)

Trading in the securities of the entity will be temporarily paused pending a further announcement. For more information, download the attached PDF.

Chimeric Therapeutics - Completion of retail component of Entitlement Offer (ASX:CHM)

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more

Chimeric Therapeutics - Security Class Suspension from Quotation CHMO (ASX:CHM)

The options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be suspended immediately, in accordance with Listing Rule 17.3, as deferred settlement trading will not be made avai...read more

Carbonxt Group - Expansion into LNG sector with new AC Pellets contract (ASX:CG1)

* Contract signed for the supply of Activated Carbon Pellets (‘AC Pellets”) to the Liquefied Natural Gas (‘LNG’) industry via a contract with Univar Solutions valued at $2 mi...read more

Chimeric Therapeutics - Final Results in Phase 1 Trial of CORE NK Platform (ASX:CHM)

* Durable Complete Response (CR) achieved with 15+ month ongoing response in one patient with high risk MDS (Myelodysplastic Syndrome) * 100% Disease Control Rate (DCR) achieved in blood cancer pat...read more

Chimeric Therapeutics - CORE NK Platform Phase 1 Clinical Data Presentation (ASX:CHM)

To view the presentation, download the attached PDF.

Chimeric partners with Be The Match Biotherapies (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has entered a strategic partne...read more

Chimeric Therapeutics - Letter to Shareholders - Rights Issue (ASX:CHM)

Dear fellow shareholders We are delighted to announce that the Board has decided to offer shareholders the opportunity to increase their ownership in Chimeric (CHM) on the same terms as instituti...read more

Chimeric Therapeutics - Entitlement Offer Notice to Eligible Retail Shareholders (ASX:CHM)

On 21 February 2022, Chimeric Therapeutics Limited (Chimeric) announced an equity raising through a 1 for 3.15 accelerated, non-renounceable entitlement offer of fully paid ordinary shares in Chimer...read more

Chimeric Therapeutics - Entitlement Offer Notice to Ineligible Retail Shareholders (ASX:CHM)

Viewing: 136 - 150 of 200 Previous | Next